ECSP055636A - Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa - Google Patents

Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa

Info

Publication number
ECSP055636A
ECSP055636A EC2005005636A ECSP055636A ECSP055636A EC SP055636 A ECSP055636 A EC SP055636A EC 2005005636 A EC2005005636 A EC 2005005636A EC SP055636 A ECSP055636 A EC SP055636A EC SP055636 A ECSP055636 A EC SP055636A
Authority
EC
Ecuador
Prior art keywords
nr4r5
heteroaryl
aryl
alkyl
heterocycloalkyl
Prior art date
Application number
EC2005005636A
Other languages
English (en)
Inventor
Janet Ann Archer
Walter Bordogna
Richard James Bull
David Edward Clark
Hazel Joan Dyke
Matthew Iain Andrew Gill
Neil Victor Harris
Den Heuvel Marco Van
Stephen Price
Original Assignee
Argenta Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218040A external-priority patent/GB0218040D0/en
Priority claimed from GB0310462A external-priority patent/GB0310462D0/en
Application filed by Argenta Discovery Ltd filed Critical Argenta Discovery Ltd
Publication of ECSP055636A publication Critical patent/ECSP055636A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Un compuesto de fórmula (I): en donde:- R1 representa arilo o heteroarilo, cada uno opcionalmente sustituido por uno o más grupos seleccionados entre R3, alquilenodioxi, carboxi, ciano, halo, hidroxi, nitro, haloalquilo, haloalcoxi, -C(=O)-R3, -C(=O)-OR3, -C(=Z)-NR4R5, -NR4R5, -NR6-C(=O)-OR3, -NR6-C(=O)-NR4R5, -NR6-C(=Z)-R3, -O-C(=O)-NR4R5, -NR6-SO2-R3, -OR3, -O-C(=O)R3, -SH, -SR3, -SOR3, -SO2R3 y -SO2-NR4R5;- R2 representa hidrógeno, cloro, ciano, fluoro, alcoxi, alquilo o haloalquilo;- R3 representa arilo, heteroarilo, cicloalquilo, cicloalquenilo, heterocicloalquilo o R7;- R4 y R5 representan independientemente un grupo seleccionado entre hidrógeno, alquilo, alquenilo, arilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo, en donde dicho alquilo o alquenilo es opcionalmente sustituido por arilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo; o el grupo -NR4R5 puede formar una amina cíclica;- R6 representa hidrógeno o alquilo inferior;- R7 representa alquilo, alquenilo y alquinilo, en donde dicho alquilo, alquenilo o alquinilo es opcionalmente sustituido por uno o más grupos seleccionados entre arilo, heteroarilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, hidroxi, -C(=Z)-NR4R5, -NR4R5, -NR6-C(=Z)-R8, -O-C(=O)-NR4R5, -NR6-C(=O)-OR8, -NR6-C(=O)-NR4R5, -NR6-SO2-R8, -OR8, -SOR8, -SO2R8 y -SO2-NR4R5; - R8 representa alquilo, alquenilo o alquinilo, opcionalmente sustituido por uno o más grupos seleccionados entre arilo, heteroarilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, hidroxi y halógeno; o R8 representa arilo, heteroarilo, cicloalquilo, cicloalquenilo o heterocicloalquilo; y- Z es O o S, y N-óxidos correspondientes, prodrogas, solvatos, y sales farmacéuticamente aceptables del mismo; y su uso para tratar una enfermedad en donde la inhibición de la histona desacetilasa puede prevenir, inhibir o mejorar la patología y/o sintomatología de la enfermedad.
EC2005005636A 2002-08-02 2005-02-28 Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa ECSP055636A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0218040A GB0218040D0 (en) 2002-08-02 2002-08-02 Chemical compounds
GB0310462A GB0310462D0 (en) 2003-05-07 2003-05-07 Chemical compounds

Publications (1)

Publication Number Publication Date
ECSP055636A true ECSP055636A (es) 2005-05-30

Family

ID=31497256

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005636A ECSP055636A (es) 2002-08-02 2005-02-28 Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa

Country Status (18)

Country Link
US (1) US20060122234A1 (es)
EP (1) EP1525199A1 (es)
JP (1) JP2005539001A (es)
KR (1) KR20050034732A (es)
CN (1) CN1684957A (es)
AR (1) AR040765A1 (es)
AU (1) AU2003255724A1 (es)
BR (1) BR0313371A (es)
CA (1) CA2494114A1 (es)
EC (1) ECSP055636A (es)
IL (1) IL166603A0 (es)
MX (1) MXPA05001334A (es)
NO (1) NO20051107L (es)
PE (1) PE20050121A1 (es)
PL (1) PL374970A1 (es)
RU (1) RU2005105696A (es)
UY (1) UY27921A1 (es)
WO (1) WO2004013130A1 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007270B1 (ru) 2002-03-13 2006-08-25 Янссен Фармацевтика Н.В. Пиперазинил-, пиперидинил- и морфолинилпроизводные как новые ингибиторы гистондеацетилазы
ES2306880T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonilamino como inhibidores novedosos de la histona desacetilasa.
AU2003218737B2 (en) 2002-03-13 2008-04-10 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
CA2476067C (en) 2002-03-13 2011-09-20 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
MXPA04012393A (es) * 2002-06-12 2005-06-17 Chemocentryx Derivados de piperazina 1-aril-4-substituidos para utilizar como antagonistas ccr1 para tratamiento de inflamacion y desordenes inmunes.
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
PL1611088T3 (pl) 2003-04-07 2009-11-30 Pharmacyclics Inc Hydroksamiany jako środki terapeutyczne
WO2005014588A1 (en) * 2003-08-01 2005-02-17 Argenta Discovery Limited Substituted thienyl-hydroxamic acids having histone deacetylase activity
US7935724B2 (en) * 2003-10-09 2011-05-03 Merck Hdac Research, Llc Thiophene and benzothiophene hydroxamic acid derivatives
US20070167499A1 (en) * 2003-10-27 2007-07-19 A*Bio Pte Ltd. Biaryl linked hydroxamates: preparation and pharmaceutical applications
CN1989131A (zh) 2004-03-30 2007-06-27 希龙公司 取代的噻吩衍生物用作抗癌药
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
UA86066C2 (ru) 2004-07-28 2009-03-25 Янссен Фармацевтика Н.В. Производные замещенного пропенилпиперазина как ингибиторы гистондеацетилазы
PL1781639T3 (pl) 2004-07-28 2012-07-31 Janssen Pharmaceutica Nv Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej
ITMI20060621A1 (it) * 2006-03-31 2007-10-01 Dac Srl Nuova classe di inibitori delle istone deacetilasi
DE102004051277A1 (de) * 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP2946810A1 (en) 2005-02-03 2015-11-25 TopoTarget UK Limited Combination therapy using an HDAC inhibitor and Vincristine for treating cancer
CA2596015A1 (en) 2005-02-14 2006-08-24 Sampath K. Anandan Fused heterocyclic compounds useful as inhibitors of histone deacetylase
AU2006226775A1 (en) * 2005-03-24 2006-09-28 Janssen Pharmaceutica, N.V. Biaryl derived amide modulators of vanilloid VR1 receptor
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
WO2006122319A2 (en) 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN102579417B (zh) 2005-05-13 2014-11-26 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
AU2006248938B2 (en) 2005-05-18 2011-09-29 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
EP1943232B1 (en) 2005-10-27 2011-05-18 Janssen Pharmaceutica NV Squaric acid derivatives as inhibitors of histone deacetylase
EP2361619A1 (en) 2005-11-10 2011-08-31 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer
JP5247470B2 (ja) 2006-01-19 2013-07-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
DK1979328T3 (da) 2006-01-19 2013-03-25 Janssen Pharmaceutica Nv Pyridin- og pyrimidinderivater i deres egenskab af histondeacetylasehæmmere
US8101616B2 (en) 2006-01-19 2012-01-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
CA2635015C (en) 2006-01-19 2014-06-03 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
DE602007001190D1 (de) 2006-01-19 2009-07-09 Janssen Pharmaceutica Nv Aminophenylderivate als neue inhibitoren von histondeacetylase
US7834011B2 (en) 2006-01-19 2010-11-16 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
GB0603041D0 (en) * 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5503874B2 (ja) * 2006-02-28 2014-05-28 ダート ニューロサイエンス （ケイマン） エルティーディー 治療化合物
BRPI0708337A2 (pt) 2006-02-28 2011-05-24 Helicon Therapeutics Inc pipirazinas terapêutica como inibidores pde4
AU2013200480B2 (en) * 2006-02-28 2016-06-09 Dart Neuroscience (Cayman) Ltd. Therapeutic compounds
GB0613518D0 (en) * 2006-07-06 2006-08-16 Phytopharm Plc Chemical compounds
EP1878730A1 (en) * 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
JP5043120B2 (ja) 2006-10-30 2012-10-10 クロマ セラピューティクス リミテッド ヒストンデアセチラーゼの阻害剤としてのヒドロキサメート
WO2008062878A1 (fr) * 2006-11-22 2008-05-29 Nihon Nohyaku Co., Ltd. Nouveau dérivé de pyrazole, agent de lutte contre des organismes nuisibles et utilisation de l'agent de lutte contre des organismes nuisibles
EP2121671A1 (en) * 2006-12-20 2009-11-25 Novartis AG 2-substituted 5-membered heterocycles as scd inhibitors
PT2099442E (pt) 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
EA201201640A1 (ru) 2007-01-30 2013-09-30 Фармасайкликс, Инк. Способы определения устойчивости рака к ингибиторам гистондеацетилазы
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008101186A1 (en) * 2007-02-15 2008-08-21 The J. David Gladstone Institutes Inhibitors for hdac8
WO2008117861A1 (ja) * 2007-03-28 2008-10-02 Santen Pharmaceutical Co., Ltd. フェニレンジアミン誘導体を有効成分とする眼圧下降剤
ES2663517T3 (es) * 2007-08-27 2018-04-13 Dart Neuroscience (Cayman) Ltd Compuestos terapéuticos de isoxazol
CA2700173C (en) 2007-09-25 2016-10-11 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
US20100249176A1 (en) * 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
BRPI0817897A2 (pt) 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
US8293513B2 (en) * 2007-12-14 2012-10-23 Georgetown University Histone deacetylase inhibitors
JP5564033B2 (ja) 2008-03-27 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規インヒビターとしてのアザ−ビシクロヘキシル置換インドリルアルキルアミノ誘導体
WO2009137081A2 (en) * 2008-05-07 2009-11-12 Massachusetts Institute Of Technology Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
AR078793A1 (es) * 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
WO2011089995A1 (ja) * 2010-01-21 2011-07-28 公立大学法人名古屋市立大学 ヒドロキサム酸誘導体及びそれを用いたｈｄａｃ８阻害剤
BR112013000925A2 (pt) 2010-07-15 2020-12-01 Bayer Intellectual Property Gmbh compostos heterocíclicos como pesticidas
WO2012052412A1 (de) 2010-10-22 2012-04-26 Bayer Cropscience Ag Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
US20140107166A1 (en) * 2011-02-14 2014-04-17 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors and methods of use thereof
NZ621221A (en) 2011-09-13 2016-07-29 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
JPWO2013141362A1 (ja) * 2012-03-23 2015-08-03 日本農薬株式会社 チアゾールカルボキサミド誘導体及びその使用方法
JP6183053B2 (ja) * 2012-08-22 2017-08-23 宇部興産株式会社 テトラヒドロピラニルピリミジン化合物の製造方法
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors
EP3062783B1 (en) 2013-10-18 2020-08-12 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
WO2015172196A1 (en) * 2014-05-13 2015-11-19 Monash University Heterocyclic compounds and use of same
CN108379585B (zh) * 2018-04-16 2020-10-16 复旦大学附属中山医院 Hdac4抑制剂在制备治疗心力衰竭的药物中的应用
CN111072582B (zh) * 2018-10-18 2024-06-18 中国药科大学 一种n－羟基芳杂环－2－甲酰胺化合物及其制备方法和用途
CN111100071A (zh) * 2019-12-19 2020-05-05 西安近代化学研究所 一种合成2-氰基-5-芳基-1h-咪唑类化合物的方法
CN119143740B (zh) * 2024-08-15 2025-11-14 杭州科兴生物化工有限公司 一种苯并噻吩类衍生物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
WO2002026696A1 (en) * 2000-09-29 2002-04-04 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors

Also Published As

Publication number Publication date
CA2494114A1 (en) 2004-02-12
MXPA05001334A (es) 2005-09-08
WO2004013130A1 (en) 2004-02-12
IL166603A0 (en) 2006-01-15
US20060122234A1 (en) 2006-06-08
AR040765A1 (es) 2005-04-20
EP1525199A1 (en) 2005-04-27
KR20050034732A (ko) 2005-04-14
PE20050121A1 (es) 2005-03-12
RU2005105696A (ru) 2005-11-10
NO20051107L (no) 2005-04-20
AU2003255724A1 (en) 2004-02-23
CN1684957A (zh) 2005-10-19
PL374970A1 (en) 2005-11-14
BR0313371A (pt) 2005-07-05
UY27921A1 (es) 2004-02-27
JP2005539001A (ja) 2005-12-22

Similar Documents

Publication Publication Date Title
CO2021003298A2 (es) Compuestos de sulfonamidaurea novedosos
PA8431301A1 (es) Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion
AR038326A1 (es) Antibacterianos feniloxazolidinonas sustituidos con heterociclicos biciclicos y composiciones relacionadas y metodos
AR040081A1 (es) Compuestos de pirrolotriazinona y su uso para tratar enfermedades
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
AR072224A1 (es) Derivados de pirimidona sustituidos
PE20160548A1 (es) Sulfonamidas como moduladores de canales de sodio
AR036103A1 (es) Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento
AR038047A1 (es) Agentes terapeuticos
ES2175161T3 (es) Derivados de piperazina como antagonistas de taquiquinina.
PE20040197A1 (es) Pirazolopiridinas sustituidas con carbamato
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
UY28333A1 (es) Inhibidores de caspasa y sus usos.
AR044078A1 (es) Dihidroquinazolinas sustituidas
AR067904A1 (es) Derivados de piperazina-amida
PA8587501A1 (es) Benzoxazinonas sustituidas y usos de las mismas
AR040278A1 (es) Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos
AR040765A1 (es) Acidos tienil-hidroxamicos sustituidos y su uso para preparar medicamentos y tratar enfermedades asociadas con la acatividad enzimatica de la histona desacetilasa
ECSP045420A (es) Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos
PA8572001A1 (es) Derivados de isoquinolina
UY27338A1 (es) Nuevos derivados de ácido sulfónico
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
PA8589801A1 (es) Aminoalcoxiindoles
AR055744A1 (es) Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos
PE47296A1 (es) Nuevo uso de derivado de indol